Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, immunotherapies, and emerging antibody–drug conjugates are helping many patients live longer—and live well. But these gains may come with risks, including one called drug-induced pneumonitis, an inflammatory reaction in the lungs that ranges from mild to life-threatening.
This article was originally published on MedicalXpress.com

